stockrowMedpace Holdings, Inc.
MEDP Healthcare Diagnostics & Research
Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.
- Revenue
- +8.50%
- EPS
- +24.6%
- Free cash flow
- −16.6%
Quarter to September 2026, against a year earlier
Follow MEDP
Alert me
Medpace Holdings, Inc. (MEDP) EPS (diluted)
Medpace Holdings, Inc.'s EPS (diluted) for fiscal 2025 was $15.28, up 21.0% from $12.63 in fiscal 2024. Over the twelve months to 30 September 2026 it was $18.04. Over the past ten years it has ranged from −$0.28 (fiscal 2015) to $15.28 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 10 consecutive fiscal years. Medpace Holdings, Inc. ranks 3rd of 49 Diagnostics & Research companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $15.28 | 20.98% |
| FY2024 | $12.63 | 42.23% |
| FY2023 | $8.88 | 21.98% |
| FY2022 | $7.28 | 51.35% |
| FY2021 | $4.81 | 25.26% |
| FY2020 | $3.84 | 43.82% |
| FY2019 | $2.67 | 35.53% |
| FY2018 | $1.97 | 101.02% |
| FY2017 | $0.98 | 164.86% |
| FY2016 | $0.37 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $4.84 | 13.88% |
| Jun 2026 | $4.25 | (0.70%) |
| Mar 2026 | $4.28 | (8.35%) |
| Dec 2025 | $4.67 | 20.98% |
| 40 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| MEDP Medpace Holdings, Inc. | $18.04 |
| LH Labcorp Holdings Inc. compare | $12.19 |
| DGX Quest Diagnostics Incorporated compare | $10.04 |
| ILMN Illumina, Inc. compare | $5.81 |
| ICLR ICON PLC compare | $5.81 |
| RVTY Revvity Inc. compare | $2.26 |
| QGEN QIAGEN N.V. compare | $1.95 |
| CRL Charles River Laboratories International, Inc. compare | $0.93 |
| GH Guardant Health, Inc. compare | −$3.68 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on MEDP
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement